BriaCell Therapeutics Corp is a clinical-stage biotechnology company dedicated to advancing immunotherapy treatments for metastatic breast cancer. The company’s lead program, Bria-IMT, employs genetically modified allogeneic breast cancer cells engineered to secrete immune-stimulatory factors, aiming to activate a patient’s immune system against tumor cells. In collaboration with clinical research organizations, BriaCell is investigating Bria-IMT both as a monotherapy and in combination with checkpoint inhibitors to enhance anti-tumor response.
In addition to Bria-IMT, BriaCell holds exclusive rights to crotoxin, a venom-derived adjuvant sourced from the South American rattlesnake Crotalus durissus terrificus. This component, known as CrotoCell, is designed to bolster the immune reaction when paired with tumor cell–based vaccines. The company’s pipeline also explores off-the-shelf vaccine constructs that leverage tumor-associated antigens to induce targeted immunity in diverse patient subsets.
Originally founded under a different name, BriaCell rebranded in 2021 to reflect its specialized focus on breast cancer immunotherapies. Headquartered in Vancouver, British Columbia, the company maintains research and development activities in North America and collaborates with European and U.S. clinical sites for its trials. Strategic partnerships with contract research organizations support BriaCell’s progression through regulatory stages and enable global trial enrollment.
BriaCell’s leadership team brings extensive expertise in oncology drug development and immunology. President and Chief Executive Officer Dr. David Pauza has over two decades of experience in immune system research, while the management team includes seasoned professionals in clinical operations, regulatory affairs and business development. Together, they guide the company’s efforts to deliver novel immunotherapeutic options for patients with advanced breast cancer.
AI Generated. May Contain Errors.
